Double Dose ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 38 | Stevens-Johnson syndrome | 1 |
| 162 | Pemphigoid | 1 |
38. Stevens-Johnson syndrome
Clinical trials : 17 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 15 - Drug target pathways : 101
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05520086 (ClinicalTrials.gov) | November 11, 2022 | 22/8/2022 | Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. | Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement. | Chronic Conjunctivitis;Stevens-Johnson Syndrome;Lyell Syndrome;Pemphigoid | Drug: Single Dose;Drug: Double Dose | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Effice Servicios Para la Investigacion S.L. | Recruiting | 18 Years | N/A | All | 20 | Phase 1/Phase 2 | Spain |
162. Pemphigoid
Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05520086 (ClinicalTrials.gov) | November 11, 2022 | 22/8/2022 | Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. | Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement. | Chronic Conjunctivitis;Stevens-Johnson Syndrome;Lyell Syndrome;Pemphigoid | Drug: Single Dose;Drug: Double Dose | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Effice Servicios Para la Investigacion S.L. | Recruiting | 18 Years | N/A | All | 20 | Phase 1/Phase 2 | Spain |